Notice2023-23628
National Institute on Drug Abuse; Notice of Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 26, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 206 (Thursday, October 26, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 206 (Thursday, October 26, 2023)]
[Notices]
[Page 73604]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-23628]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Drug Abuse.
The meeting will be held as a virtual meeting and is open to the
public, as indicated below. Individuals who plan to view the virtual
meeting and need special assistance such as sign language
interpretation or other reasonable accommodations to view the meeting,
should notify Dr. Jeanette Marketon via email at
<a href="/cdn-cgi/l/email-protection#79131c18171c0d0d1c5714180b121c0d161739171011571e160f"><span class="__cf_email__" data-cfemail="0d67686c636879796823606c7f66687962634d636465236a627b">[email protected]</span></a> five days in advance of the meeting. The open
session will be videocast and can be accessed from the NIH Videocasting
and Podcasting website (<a href="http://videocast.nih.gov/">http://videocast.nih.gov/</a>).
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6),
Title 5 U.S.C., as amended. The intramural programs and projects as
well as the grant applications and/or contract proposals and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with intramural programs and projects
as well as the grant applications and/or contract proposals, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: February 6, 2024.
Closed: 10:30 a.m. to 11:45 a.m. Agenda: To review and evaluate
grant applications.
Closed: 11:45 a.m. to 12:15 p.m. Agenda: Report to Council from
the NIDA Board of Scientific Counselors (BSC).
Open: 12:45 p.m. to 5:00 p.m. Agenda: Presentations and other
business of the Council.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown
Street, Bethesda, MD 20852 301-443-6480 <a href="/cdn-cgi/l/email-protection#fb888c9e928888bb95929f9ad5959293d59c948d"><span class="__cf_email__" data-cfemail="255652404c5656654b4c41440b4b4c4d0b424a53">[email protected]</span></a>.
Contact Person: Jeanette Marketon, Ph.D., Director, Office of
Extramural Policy, Division of Extramural Research Office of
Extramural Policy, National Institute on Drug Abuse, NIH, Three
White Flint North, RM 09C68, 11601 Landsdown Street, Bethesda, MD
20852, 301-443-5239 <a href="/cdn-cgi/l/email-protection#e9838c88878c9d9d8cc784889b828c9d8687a9878081c78e869f"><span class="__cf_email__" data-cfemail="7b111e1a151e0f0f1e55161a09101e0f14153b151213551c140d">[email protected]</span></a>.
Any interested person may file written comments with the
committee by forwarding the statement to Dr. Jeanette Marketon at
<a href="/cdn-cgi/l/email-protection#5a303f3b343f2e2e3f74373b28313f2e35341a343332743d352c"><span class="__cf_email__" data-cfemail="87ede2e6e9e2f3f3e2a9eae6f5ece2f3e8e9c7e9eeefa9e0e8f1">[email protected]</span></a>. The statement should include the name,
address, telephone number and when applicable, the business or
professional affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: <a href="http://www.drugabuse.gov/NACDA/NACDAHome.html">www.drugabuse.gov/NACDA/NACDAHome.html</a>, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: October 20, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2023-23628 Filed 10-25-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 26, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.